Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
A 58-year-old man had adrenocortical carcinoma in the right adrenal gland. The tumour secreted excessive cortisol and dehydroepiandrosterone-sulphate (DHEA-S), and had invaded the right hepatic lobe and vena cava. Eleven months after surgical tumour resection, the serum DHEA-S levels again increased. Local tumour recurrence and a metastasis was found in the lung. Eleven months after surgery chemotherapy with mitotane (o,p'-DDD) was initiated. Twelve weeks of mitotane reduced serum DHEA-S levels and caused these tumours to disappear. The patient was then treated with low-dose mitotane (1.5-2.0 g/day) for 2 years. Serum levels of mitotane remained at less than 10 microg/ml. Although such low serum levels of mitotane and delayed initiation of mitotane after surgery have been proposed to weaken the antineoplastic effect of mitotane, the patient had a remission for 2 years. However, there was then local re-recurrence with an increase in serum DHEA-S and death 4 months later. The histological features of neoplastic cells were quite different comparing tumour resected at surgery and tumour at autopsy. The latter had more frequent mitotic nuclei. This tumour was initially sensitive to mitotane, but later became insensitive.
Seki
M
M
Department of Medicine, Institute of Clinical Endocrinology, School of Medicine, Tokyo Women's Medical University, Japan.
Nomura
K
K
Hirohara
D
D
Kanazawa
M
M
Sawada
T
T
Takasaki
K
K
Demura
H
H
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D018268:Adrenocortical Carcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003687:Dehydroepiandrosterone / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D012074:Remission Induction
D018931:Antineoplastic Agents, Hormonal; D003687:Dehydroepiandrosterone; D008939:Mitotane